Dr Reddy’s, Merck’s Covid pill partner in India, sees a short-lived boom

And this is despite Dr Reddys, one of Indias largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod to produce Mercks antiviral drug molnupiravir within weeks. The reason: multiple licensees for the Merck drug will cap profits and manufacturing glitches for Sputnik have led to loss of precious time as the worlds second-most populous nation was ramping up its inoculation drive.

via Economictimes